Companies: 10,795·Total market cap: $144.5T
BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.

BTAINASDAQHealthcare● Active
$1.11
+$0.00(+0.00%)
Market Cap$34119748
P/E Ratio
52W High$8.08
52W Low$1.01
Overview

BioXcel Therapeutics, Inc. (BTAI) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BTAI · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-6.70btai eps ttm · btai earnings per shareEarnings history
PE Ratio (TTM)btai pe ratio ttm · btai price to earningsPE Ratio deep dive
Revenue (TTM)680000.00btai revenue ttm · btai annual revenueFull revenue history
Dividend YieldNo Dividenddoes btai pay dividends · btai dividend yieldDividend history
Shares Outstanding12.2Mbtai shares outstanding · btai floatShares outstanding history
Next EarningsAug 11, 2026Est.btai earnings date · btai next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$642000.00▼ 71.67% YoY
202320242025
bioxcel therapeutics, inc. revenue · btai revenue 2025
FY 2025Net Income-$69.9M▼ 17.28% YoY
202320242025
bioxcel therapeutics, inc. net income · btai profit 2025
FY 2025EPS$-5.73▲ +75.63% YoY
202320242025
btai eps · bioxcel therapeutics, inc. earnings per share 2025
TTM:Revenue: $680000.00Net Income: -$75.3MEPS: $-6.70View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy15 analystsis btai a buy · btai analyst rating
Strong Buy
0
Buy
8
Hold
6
Sell
1
Strong Sell
0
12-Month Price Target
$1.00Low
$1.10Current
$12.00Avg Target985.97% upside
$25.00High
btai price target · btai 12 month forecast

Total: 15 · Buy rate: 53.3%

The BTAI analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $12.00, representing +985.97% upside from the current price of $1.10.

Stock Performance

Full History
1D+0.00%
1W-7.92%
1M-9.43%
3M-25.34%
YTD-30.94%
1Y-43.62%
5Y-99.82%

About BioXcel Therapeutics, Inc.

CEOVimal D. Mehta
IPO DateMar 8, 2018
Employees37
CountryUS

BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative ther…

what is bioxcel therapeutics, inc. · btai stock overview · bioxcel therapeutics, inc. company profile · who is bioxcel therapeutics, inc. ceo · btai NASDAQ · bioxcel therapeutics, inc. headquarters · bioxcel therapeutics, inc. business segments

About Stock Overview & Key Data

BioXcel Therapeutics, Inc. (BTAI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 8, 2018. As of the latest trading session, BTAI stock price is $1.10, with a market capitalization of $34.1M. The stock has returned -43.62% over the past 12 months and -30.94% year-to-date.

According to 15 Wall Street analysts, the consensus rating for BioXcel Therapeutics, Inc. stock is Buy, with an average 12-month price target of $12.00. In fiscal year 2025, BioXcel Therapeutics, Inc. reported revenue of $642000.00 and net income of -$69.9M. For detailed data — including BioXcel Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, BioXcel Therapeutics, Inc. (BTAI) stock price is $1.10. The stock is traded on NASDAQ under the ticker symbol BTAI. The 52-week range is $1.01 – $8.08.

BTAI stock priceBTAI quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice